Promising areas of research on the pharmacogenetics of dabigatran etexilate

Dabigatran etexilate is a prodrug of dabigatran, a direct inhibitor of thrombin. Pharmacokinetics of dabigatran etexilate doesn’t have the disadvantages of vitamin K antagonists. It is considered that CES1 enzyme and P-glycoprotein (CES1 and ABCB1 genes accordingly) play important role in pharmacokinetics of dabigatran etexilate. UDP-glucuronosyltransferase enzymes UGT2B15, UGT1A9, UGT2B7 (UGT2B15, UGT1A9, UGT2B7 genes accordingly) take part in the metabolism of active dabigatran. Presence of these gene’s single-nucleotide variants (SNV) can affect effectiveness and safety of dabigatran etexilate usage. The goal of this review is analysis of promising areas of associated researches of SNV of genes CES1 and ABCB1 and search for new candidate genes that reveal effectiveness and safety of dabigatran etexilate usage.

1. Drugs.com. FDA Approves Pradaxa. [Internet]. [cited 2020 June 15] Available from: www.drugs.com/newdrugs/fda-approves-pradaxa-preventstroke-atrial-fibrillation-2370.html. Last updated date: October 2010.

2. Drugs.com. FDA Approves Pradaxa for deep venous thrombosis and pulmonary embolism. [Internet]. [cited 2020 June 15] Available from: www.drugs.com/newdrugs/fda-approves-pradaxa-deep-venous-thrombosispulmonary-embolism-4030.html. Last updated date: April 2014. дальнейшем исследовании. Роль генов, кодирующих ферменты глюкуронизации дабигатрана (UGT2B15, UGT1A9, UGT2B7), в его эффективности и безопасности недостаточно изучена, однако ген UGT2B15, кодирующий фермент UGT2B15, может являться потенциальным геном-кандидатом для исследования безопасности применения препарата. ДОПОЛНИТЕЛЬНАЯ ИНФОРМАЦИЯ Конфликт интересов: авторы декларируют отсутствие конфликта интересов. Участие авторов: Савинова А.В. — написание текста; Шнайдер Н.А., Петрова М.М., Насырова Р.Ф. — обсуждение дизайна рисунков, редактирование, финальное утверждение рукописи.

3. Drugs.com. FDA Approves Pradaxa for prophylaxis of deep venous thrombosis and pulmonary embolism after hip replacement surgery. [Internet]. [cited 2020 June 15] Available from: www.drugs.com/newdrugs/fda-approvespradaxa-prophylaxis-deep-venous-thrombosis-pulmonary-embolism-afterhip-replacement-4304.html. Last updated date: November 2015.

4. Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombininhibitor, inhealthymalesubjects. Br J Clin Pharmacol. 2007;64(3): 292–303. DOI: 10.1111/j.1365-2125.2007.02899.x.

5. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123(13):1436–1450. DOI: 10.1161/CIRCULATIONAHA.110.004424.

6. Goldsack NR, Chambers RC, Dabbagh K, Laurent GJ. Thrombin. Int J Biochem Cell Biol. 1998;30(6):641–646. DOI: 10.1016/s1357-2725(98)00011-9.

7. Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost 2006;32(1):3–15. DOI: 10.1055/s-2006-939550.

8. Comin J, Kallmes DF. Dabigatran (Pradaxa). American Journal of Neuroradiology. March 2012;33(3):426-428. DOI: 10.3174/ajnr.a3000.

9. Dimatteo C, D’Andrea G, Vecchione G, et al. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016;144:1–5. DOI: 10.1016/j.thromres.2016.05.025.

10. Shi J, Wang X, Nguyen JH et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016; 119:76–84. DOI: 10.1016/j.bcp.2016.09.003.

11. Chen Z, Shi T, Zhang L et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016;370(1):153–164. DOI: 10.1016/j.canlet.2015.10.010.

12. Ebner T, Wagner K, Wienen W. Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010;38(9):1567–1575. DOI: 10.1124/dmd.110.033696.

13. Paré G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127(13):1404– 1412. DOI: 10.1161/CIRCULATIONAHA.

14. Gouin-Thibault I, Delavenne X, Blanchard A et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017;15(2):273–283. DOI: 10.1111/jth.13577.

15. Сычев Д.А., Абдуллаев Ш.П., Мирзаев К.Б., и др. Генетические детерминанаты безопасности применения прямого ингибитора тромбина среди этнических групп Российской Федерации // Биомедицина 2019;(1):78–94. [Sychev DA, Abdullaev SP, Mirzayev KB et al. Genetic determinants of the safety of dabigatran (ces1 gene rs2244613 polymorphism) for the Russian population: a multi-ethnic analysis. Journal Biomed. 2019; (1):78–94. (In Russ).]. DOI: 10.33647/2074-5982-15-1-78-94.

16. Сычев Д.А., Леванов А.Н., Шелехова Т.В., и др. Влияние полиморфизма генов abcb1 и ces1 на уровни равновесных концентраций дабигатрана у пациентов после эндопротезирования коленного сустава // Атеротромбоз. 2018;(1):122–130. [Sychev DA, Levanov AN et al. Impact of abcb1 and ces1 genetic polymorphisms on trough steady-state dabigatran concentrations in patients after endoprosthesis of knife join. Atherothrombosis. 2018;(1):122–130. (In Russ).]. DOI: 10.21518/2307-1109-2018-1-122-130.

17. Sychev D, Skripka A, Ryzhikova K et al. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease. Drug Metab Pers Ther. 2020 Mar 5;35(1):/j/dmdi.2020.35.issue-1/dmpt-2019- 0029/dmpt-2019-0029.xml. DOI: 10.1515/dmpt-2019-0029.

18. He X, Hesse LM, Hazarika S, et al. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol. 2009;68(5):721–730. DOI: 10.1111/j.1365-2125.2009.03519.x.

19. Court MH, Zhu Z, Masse G et al. Race, gender, and genetic polymorphism contribute to variability in acetaminophen pharmacokinetics, metabolism, and protein-adduct concentrations in healthy African-American and European-American volunteers. J Pharmacol Exp Ther. 2017;362(3):431– 440. DOI: 10.1124/jpet.117.242107.

20. Савельева М.И., Урванцева И.А., Игнатова А.К., и др. Фармакогенетические особенности II фазы биотрансформации тамоксифена: систематический обзор // Фармакогенетика и фармакогеномика – 2017. – № 1. – С. 10–15. [Savelyeva MI, Urvantseva IA, Ignatova AK et al. Pharmacogenetic features of the phase II biotransformation of tamoxifen: a systematic review. Pharmacogenetics and Pharmacogenomics 2017;(1): 10–15. (In Russ).].

21. Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol. 2003;65(9):1441–1419. DOI: 10.1016/s0006-2952(03)00076-5.

22. Stringer F, Ploeger BA, DeJongh J et al. Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar. J Clin Pharmacol. 2013;53(3):256–263. DOI: 10.1177/0091270012447121.